Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report
| Class:Id | LiteratureReference:9713872 |
|---|---|
| _displayName | ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report |
| _timestamp | 2021-02-02 01:30:01 |
| author | [Person:9713871] Xu, Xiaojing [Person:9713865] Li, Hong [Person:9713869] Peng, Ke [Person:9713866] Yu, Yiyi [Person:9713873] Chen, Lingli [Person:9713874] Fang, Yong [Person:9713868] Sun, Yihong [Person:9713870] Hou, Yingyong [Person:9713867] Liu, Tianshu |
| created | [InstanceEdit:9713875] Rothfels, Karen, 2021-02-02 |
| journal | Oncol Lett |
| pages | 2370-2376 |
| pubMedIdentifier | 30675302 |
| title | ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report |
| volume | 17 |
| year | 2019 |
| (literatureReference) | [FailedReaction:9715357] crizotinib-resistant ALK mutants don't bind crizotinib [Homo sapiens] [DefinedSet:9700564] crizotinib resistant ALK mutants [plasma membrane] [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report (9713872)
